Navigation Links
CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
Date:1/31/2008

"may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new
'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. CuraGen Corporation Receives Notification from NASDAQ
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Marktech Optoelectronics is pleased to introduce ... have an internal gain mechanism, fast time response, low ... region. These APD’s are recommended for applications that require ... overcome high pre-amp noise. In addition, Marktech APD's provide ... for extreme low-level light detection and short pulse detection. ...
(Date:6/2/2015)... , June 2, 2015 TapImmune, Inc. ... its institutional investors have reached an agreement whereby the ... short term warrants to provide the Company up to ... an effective S-1 registration statement. Under the restructured terms ... also call additional warrants which could result in a ...
(Date:6/2/2015)... 02, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company with interests in the natural wellness sector ... technology, today announced that it has officially extinguished ... in exchange for a one-time cash payment of ... and Typenex entered into a Settlement Agreement (the ...
(Date:6/2/2015)... 02, 2015 Cirrascale Corporation ... and rackmount computing and storage infrastructure for conventional ... of its high density scale-out, two-in-one video delivery ... RM1622D . The high density, two-in-one system supports ... family with Intel® Iris™ Pro graphics P6300 and ...
Breaking Biology Technology:Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... RIDGE, Colo., Oct. 8 GeneThera, Inc.,(Pink Sheets: ... company,s Chairman and CEO, Dr. Tony Milici, is ... Show., The interview gives viewers an overview ... latest press release., To view the ...
... Develop Dopexamine as Part of Proprietary Post-Surgery ... ... Circassia Ltd, a specialty,biopharmaceutical company focused on the fields ... the US, Canadian and Japanese,development and commercialization rights to dopexamine ...
... health, LONDON, Oct. 7 A study published ... the international,effort to eliminate lymphatic filariasis (LF) has made ... most debilitating diseases.,The study found that the LF elimination ... stopped another 9.5 million people already,infected with the disease ...
Cached Biology Technology:[video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.net's 3-Minute Press Show 2Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 2LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 3LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 4
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/7/2015)... Fingerprint Cards (FPC) introduces ... FPC,s smallest touch fingerprint sensors to date.  ... integration on the backside of the phone, and ... to integrate touch fingerprint sensors in the OEMs, ... for module manufacturers to customize the look and ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... project E! 3424 RECAN has developed a range of ... the proteins produced in the blood which counteract bacteria, ... producing a number of recombinant proteins which are important ... have direct uses in immunisation and experimental studies. A ...
... million commitment from the Robertson Foundation to create a ... Medicine,s pioneering cell therapy research and treatment programs for ... brain injuries suffered at birth. In making the announcement, ... University, and Chief Executive Officer for Duke University Health ...
... trees shows that California,s western Sierra Nevada was droughty and ... Scientists reconstructed the 3,000-year history of fire by ... giganteum , in the Giant Forest of Sequoia National Park. ... "It,s the longest tree-ring fire history in the world, ...
Cached Biology News:Manufacturing antibodies 2Manufacturing antibodies 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3Giant sequoias yield longest fire history from tree rings 2Giant sequoias yield longest fire history from tree rings 3
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Prepared in distilled water....
Biology Products: